• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CDXS

CDXS

Codexis, Inc.

NASDAQHealthcareBiotechnologyUS

USD2.72

+0.03 (+1.12%)

Rating:D+

Company Profile

CEO

Alison Moore

IPO Date

2010-04-22

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.67

Prev. Close

$2.69

Day Low

$2.63

Day High

$2.79

52W Low

$0.96

52W High

$3.87

Market Cap

$0.25B

Volume

0.70M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

58.7%

Avg Negative

2.7%

Avg Neutral

38.1%

News Feed

After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright

Zacks Investment Research·8/10/2021·↑ positive

Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/7/2021·↓ negative

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·8/5/2021·↑ positive

Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient

GlobeNewsWire·8/2/2021·↑ positive

Codexis Earns Milestone Payment from GlaxoSmithKline

GlobeNewsWire·7/7/2021·↑ positive

Strength Seen in Codexis (CDXS): Can Its 12.6% Jump Turn into More Strength?

Zacks Investment Research·6/21/2021·↑ positive

Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

Benzinga·6/18/2021·↑ positive

Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product

GlobeNewsWire·6/17/2021·↑ positive

Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder

GlobeNewsWire·6/10/2021·↑ positive

Codexis to Participate in Upcoming Virtual Healthcare Conferences

GlobeNewsWire·5/17/2021·↑ positive